No appetite suppression on 2.5mg Mounjaro: what's actually happening

Why the starter dose isn't designed to suppress appetite

The decision about whether something is 'working' at 2.5mg hinges on understanding what that dose is actually for. Tirzepatide's licensed treatment schedule, published in its Summary of Product Characteristics on the Electronic Medicines Compendium, begins at 2.5mg for a single reason: tolerability. At that level, the dose is low enough that your gut adjusts to slowed gastric emptying without the nausea, vomiting or digestive discomfort that can come with jumping straight to a therapeutic level.

This matters because it reframes the question. The absence of appetite suppression on 2.5mg is not a sign of non-response, it is, in most cases, exactly what the schedule predicts. The dose is calibrated to get you through the first four weeks, not to produce the fullness signals that characterise the medicine's effect at higher strengths.

Think of it like this: if you keep your pen in the fridge door and take it once a week, your routine is already established. The appetite effect follows the dose increase, not the habit. Titrating to 5mg after four weeks (as the standard schedule allows) is where most people first notice a genuine shift in hunger and satiety. You can read more about what to expect from the 2.5mg dose in detail, including what the first four weeks typically look like.

The biology behind the delayed effect

Tirzepatide works by activating two hormone receptors simultaneously: GLP-1 and GIP. Both are involved in appetite signalling, glucose regulation and the rate at which food leaves your stomach. At 2.5mg, the concentration of the medicine in your system is building toward a steady state, peak plasma levels after weekly dosing are typically reached over several weeks of consistent dosing, not on day one.

The NHS tirzepatide medicines page makes clear that weight loss is expected to occur gradually, with the strongest effects at higher doses. This is consistent with what SURMOUNT-1, the pivotal phase 3 trial, demonstrated: the participants who achieved the greatest weight reductions (around 20–21% at 72 weeks on 15mg) reached those results through a structured titration, not by staying at the starting level. The 2.5mg period is the foundation, not the outcome.

For a fuller look at how the therapeutic doses compare and what effects people typically report at 5mg, the Mounjaro therapeutic dose page is worth reading alongside this one. Understanding the full dose range also helps if you're considering what progression looks like from here. Our overview of Mounjaro for weight management covers the complete picture.

When to raise it with your prescriber

Deciding whether to act on the absence of appetite suppression at 2.5mg really comes down to timing. If you are still in your first four weeks, the clinical answer is usually: wait for the titration. The dose increase to 5mg is where the conversation about appetite suppression genuinely begins.

If you have moved to 5mg and still feel no difference in hunger, satiety or food intake, that is a different situation and worth discussing directly with your prescriber. Some people are slower to notice subjective appetite changes even as metabolic processes shift; others may benefit from a different approach to titration or additional lifestyle support. Your prescriber reviews the full picture before any decision about your next dose step.

There is no value in guessing or self-adjusting. The guide to moving from 2.5mg to 5mg explains what that transition typically involves and what to expect. If appetite suppression remains a concern at 5mg, our page on no suppression at 5mg Mounjaro addresses that specific situation in more depth. For a broader view of what drives costs across your treatment course, the Mounjaro pricing page sets out what private treatment typically involves, clearly and without hidden extras.

If you are ready to discuss your situation with a clinician, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, not an automated system.